The company attributed the revenue decline in part to working capital restraints and long manufacturing lead times, which are being addressed currently.
The firm said it anticipates using the financing for further commercialization and expansion of its infectious disease testing vertical, among other activities.
CEO Prahlad Singh said the firm is developing a PCR- and antibody-based assay for the novel coronavirus 2019-nCoV and is working with the Chinese NMPA.
The final national coverage decision stipulates that NGS germline tests for assessing hereditary breast and ovarian cancer risk must have FDA's blessing.
Memorial Hermann's outreach sites will transfer testing to Quest's Houston lab and the firm will also provide management services for the system's 21 hospital labs.
The pharmacogenetic test, which runs on a platform from British company Genedrive, will be tested in two neonatal intensive care units in Manchester and Liverpool.
The agency plans to make test kits available to state and international partners in the next two weeks. It also provided updated information about the virus.
Natera alleged that certain cell-free DNA-based oncology products sold by Archer Dx infringe its US Patent 10,538,814, which was issued earlier this month.
Myriad filed an sPMA for myChoice CDx despite GSK's confidence that Zejula will be approved in newly diagnosed ovarian cancer regardless of biomarker status.
FIND said that the consortium will evaluate the impact on clinical trial participants of innovative diagnostic technologies versus current standards of care.
The partners will extend the lung cancer biomarker study to countries in and outside Europe, and see if liquid biopsy could offer benefits to tissue-based testing.
Blueprint provides 3,900 targeted single-gene and more than 200 panel tests covering 14 medical specialties, leveraging NGS and bioinformatics methods.
